LDL-C对缺血性卒中与冠心病的相对效应:孟德尔随机化研究
本研究采用两样本孟德尔随机化方法,基于62个独立遗传变异,评估终身LDL-C差异对缺血性卒中和冠心病的因果效应。结果显示,遗传决定的LDL-C每升高1 mmol/L,冠心病风险增加49%(OR 1.49,95%CI 1.32-1.68),而缺血性卒中风险仅增加12%(OR 1.12,95%CI 0.96-1.30,p=0.14),两者异质性显著(p=2.6×10⁻³),提示LDL-C对缺血性卒中的因果效应弱于冠心病。
要点
- 遗传决定的LDL-C升高对冠心病风险效应显著,对缺血性卒中效应较弱且不显著。
- LDL-C对心源性栓塞性卒中的效应更弱(OR 1.06,95%CI 0.84-1.33)。
- LDL-C对缺血性卒中与冠心病的效应存在显著异质性(p=2.6×10⁻³)。
核心结论
- 遗传变异决定的终身LDL-C差异对缺血性卒中的效应弱于对冠心病的效应,与降LDL-C治疗对两者一致的效果形成对比。
研究设计与样本
- 两样本孟德尔随机化研究,基于62个独立且全基因组显著的LDL-C相关遗传变异,利用METASTROKE的12,389例缺血性卒中病例和CARDIoGRAMplusC4D的60,801例冠心病病例的汇总数据进行因果推断。
主要发现
- 遗传决定的LDL-C每升高1 mmol/L,冠心病风险OR为1.49(95%CI 1.32-1.68,p=1.1×10⁻⁸)。
- 遗传决定的LDL-C每升高1 mmol/L,缺血性卒中风险OR为1.12(95%CI 0.96-1.30,p=0.14)。
- 遗传决定的LDL-C每升高1 mmol/L,心源性栓塞性卒中风险OR为1.06(95%CI 0.84-1.33,p=0.64)。
- LDL-C对缺血性卒中与冠心病效应的异质性检验p=2.6×10⁻³;对心源性栓塞性卒中与冠心病效应的异质性检验p=8.6×10⁻³。
临床怎么用
- 解读LDL-C与卒中关系时需考虑卒中病因亚型,心源性栓塞性卒中受LDL-C因果影响可能较小。
局限性
- 原文未明确报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the causal relevance of lifelong differences in low-density lipoprotein cholesterol (LDL-C) for ischemic stroke (IS) relative to that for coronary heart disease (CHD) using a Mendelian randomization approach. METHODS: We undertook a 2-sample Mendelian randomization, based on summary data, to estimate the causal relevance of LDL-C for risk of IS and CHD. Information from 62 independent genetic variants with genome-wide significant effects on LDL-C levels was used to estimate the causal effects of LDL-C for IS and IS subtypes (based on 12,389 IS cases from METASTROKE) and for CHD (based on 60,801 cases from CARDIoGRAMplusC4D). We then assessed the effects of LDL-C on IS and CHD for heterogeneity. RESULTS: A 1 mmol/L higher genetically determined LDL-C was associated with a 50% higher risk of CHD (odds ratio [OR] 1.49, 95% confidence interval [CI] 1.32-1.68, p = 1.1 × 10-8). By contrast, the causal effect of LDL-C was much weaker for IS (OR 1.12, 95% CI 0.96-1.30, p = 0.14; p for heterogeneity = 2.6 × 10-3) and, in particular, for cardioembolic stroke (OR 1.06, 95% CI 0.84-1.33, p = 0.64; p for heterogeneity = 8.6 × 10-3) when compared with that for CHD. CONCLUSIONS: In contrast with the consistent effects of LDL-C-lowering therapies on IS and CHD, genetic variants that confer lifelong LDL-C differences show a weaker effect on IS than on CHD. The relevance of etiologically distinct IS subtypes may contribute to the differences observed.
引用
- Valdes-Marquez E, Parish S, Clarke R, et al. Relative effects of LDL-C on ischemic stroke and coronary disease: A Mendelian randomization study. Neurology. 2019. PMID: 30787162. doi:10.1212/WNL.0000000000007091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。